11 results about "Viroid" patented technology

The application discloses a kind of virus-like hierarchical microspheres of Cu doped SnO2 with adjustable morphology prepared by molten salt method, preparation method and application thereof.Using the strategy of template pyrolysis-molten salt synergistic regulation, CuO / SnO2 p-n heterojunction material with unique virus-like multi-level structure is successfully constructed.Firstly, pure phase SnO2 microsphere substrate is obtained by liquid phase deposition combined with calcination, then it is mixed with molten salt and copper salt, and directional induction effect of molten salt polarity environment on crystal growth is used, so that controllable epitaxial growth of SnO2 microsphere surface needle-like structure virus-like spike morphology and in-situ doping of Cu atom are realized through two-stage heat treatment, and finally virus-like hierarchical microspheres with dense needle-like protrusions on the surface are formed.When it is applied to H2S sensor, based on the "insulation-metal" phase transition effect triggered by specific reaction of CuO and H2S, the response value to 10 ppm H2S is as high as 57269 at low working temperature of 160 DEG C, which is improved by 2 orders of magnitude compared with similar materials, and it also shows excellent long-term stability (decay rate <5% for 30 days).

The present application relates to the fields of biotechnology and agricultural fishery, and discloses application of star anise water extract in preparation of an inhibitor of CyHV-2, and the technical scheme finds that the star anise water extract can effectively inhibit the infection and replication of CyHV-2 virus in GiCF cells. The present application firstly applies the star anise water extract to prevent and treat the infection of CyHV-2 (CyHV-2), thereby providing a new treatment scheme for CyHV-2 virus. The star anise water extract can effectively reduce the copy number of CyHV-2 virus, and the star anise water extract can be used to prepare a medicine for preventing and treating the infection of CyHV-2, and a medicine for treating viral hematopoietic organ necrosis disease of fish.

The application discloses a kind of MS2 virus-like particles based on capsid protein site-directed mutation and its preparation method and application, belong to molecular biological technique field.The amino acid of the beta sheet interface of capsid protein sequence, the amino acid of the interface when two capsid proteins molecules assemble, the carboxyl end site of capsid protein is subjected to site-directed mutation, obtain the mutant that can significantly improve the assembly efficiency and stability of capsid protein dimer.Utilize the mutant to construct MS2 virus-like particles, further by the design of mature enzyme and capsid protein expression element, control mature enzyme weak expression, capsid protein strong expression, to improve assembly efficiency.The application improves the assembly efficiency of MS2 virus by the above strategy, improves the proportion of wrapped RNA, enhances the stability of virus-like particle, greatly prolongs the stable storage time of RNA, improves the purity of wrapped RNA.

The application discloses a kind of single-chain small deoxyribonucleic acid targeting multiple viruses and application thereof.The nucleotide sequence of the single-chain small deoxyribonucleic acid is 5'-ACAGGGTTTTCACCCTTCCTT-3', which targets the highly conserved region of 9 kinds of viruses infecting tomato, realizes the synergistic silencing effect of "one target multi-control". Compared with traditional ds-sRNA, the ss-sDNA of the application shows higher stability and viroid RNA interference efficiency in plants. Experiments prove that, compared with ds-sRNA, 20-25 μM concentration of ss-sDNA foliar spraying or stem injection can reduce the titers of 9 kinds of viruses and plant disease index by 10%-39% and 3.3%-17.4% respectively. The application provides a new type of nucleic acid pesticide for viroid disease, which is efficient, broad-spectrum and environment-friendly.

This invention provides a method for efficient multi-gene editing and CAR site-directed integration based on BaEV envelope glycoprotein truncated viral particles and its application in immune cell engineering. The invention provides an MLV-VLP system utilizing BaEV envelope glycoprotein truncated particles to achieve efficient CRISPR-Cas9 delivery without electroporation or the use of randomly integrating viruses. Combined with adeno-associated virus (AAV6) delivery of HDR templates, it enables efficient site-directed integration of CAR sequences at target sites (such as TRAC, PD1, and B2M) in primary human T cells and NK cells. The prepared CAR-T or CAR-NK cells exhibit excellent cell killing, proliferation, and low exhaustion characteristics in vitro, achieving 100% tumor clearance in an in vivo mouse model. It can simultaneously achieve multi-gene knockout with high efficiency, supporting large-scale allogeneic CAR-T and CAR-NK cell production.

The application discloses a Plectropomus leopardus spleen cell line and application thereof. Plectropomus leopardus The spleen cell line PLS has a preservation number of GDMCC No: 68131. The PLS is obtained through primary culture and multiple subculture, has a fast cell growth speed, has been stably subcultured for more than 60 generations, has good activity after cryopreservation, and lays a foundation for Plectropomus leopardus gene germplasm resource preservation. Meanwhile, the PLS is sensitive to fish nervous necrosis virus and iridovirus, can be applied to exogenous gene function research, fish virus isolation, virus infection pathogenesis, virus host interaction and virus in-vitro infection model, and provides a high-efficiency amplification system for Plectropomus leopardus virus vaccine preparation.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.

The present application relates to the fields of biotechnology and agricultural fishery, and discloses application of curcumin in preparation of an inhibitor of CyHV-2, and finds that curcumin can effectively inhibit the infection and replication of CyHV-2 virus in GiCF cells.The present application first applies curcumin to the prevention and treatment of CyHV-2 infection, thereby providing a new treatment scheme for CyHV-2 virus.Curcumin can effectively reduce the copy number of CyHV-2 virus, and curcumin can be used to prepare a drug for preventing and treating CyHV-2 infection, and a drug for treating viral hematopoietic organ necrosis in fish.

This invention relates to the field of wet wipes technology, specifically a composite disinfectant and bactericidal wet wipe, comprising non-woven fabric and a wet wipe liquid. The wet wipe liquid comprises the following components by weight: 80-90 parts purified water, 5-10 parts plant extract, 4-6 parts humectant, 0.5-1 part glycerin, 8-12 parts chitosan, 1-2 parts slow-release solution, 2-5 parts bactericide, and 5-10 parts lysozyme. The plant extract, glycerin, and chitosan are weighed and added to an appropriate amount of purified water, then stirred thoroughly. The slow-release solution, bactericide, and lysozyme are weighed and stirred thoroughly until homogeneous. The humectant is weighed and replenished with purified water, then stirred thoroughly to obtain the composite disinfectant and bactericidal solution. The non-woven fabric is then soaked layer by layer in the composite disinfectant and bactericidal solution to obtain the composite disinfectant and bactericidal wet wipe. This invention can quickly kill various viruses and bacteria on the surface of the human body or objects through wiping, and is non-toxic and harmless to the human body. It is also convenient to carry and can be stored for a long time.

The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.

This invention provides a recombinant Pasteurella multocida toxin protein having three antigenic determinants of the Pasteurella multocida toxin protein. The three antigenic determinants have sequences as shown in SEQ ID NOs:2, 3, and 4, respectively. This invention also provides a virus-like particle containing the aforementioned recombinant Pasteurella multocida toxin protein, a nucleic acid sequence encoding the aforementioned recombinant Pasteurella multocida toxin protein or encoding the virus-like particle containing the aforementioned recombinant Pasteurella multocida toxin protein, and a porcine atrophic rhinitis immune composition containing the aforementioned recombinant Pasteurella multocida toxin protein and / or the virus-like particle containing the aforementioned recombinant Pasteurella multocida toxin protein.